{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:07:14Z","timestamp":1775477234093,"version":"3.50.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K022539\/1"],"award-info":[{"award-number":["MR\/K022539\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_PC_16058"],"award-info":[{"award-number":["MC_PC_16058"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003965","name":"Migraine Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003965","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Finnish Academy","doi-asserted-by":"crossref","award":["325392"],"award-info":[{"award-number":["325392"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012528","name":"Kazan Federal University","doi-asserted-by":"publisher","award":["0671-2020-0059"],"award-info":[{"award-number":["0671-2020-0059"]}],"id":[{"id":"10.13039\/501100012528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s13311-020-00967-7","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T14:02:30Z","timestamp":1605621750000},"page":"556-568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine"],"prefix":"10.1016","volume":"18","author":[{"given":"Anna P.","family":"Andreou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Leese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Greco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Demartini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Corrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Zanaboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ksenia","family":"Koroleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph O.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Lambru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciara","family":"Doran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg","family":"Gafurov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Seward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashid","family":"Giniatullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Tassorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-3275","authenticated-orcid":false,"given":"Bazbek","family":"Davletov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1007\/s13311-020-00967-7_bib1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1474-4422(18)30085-1","article-title":"International Classification of Headache Disorders","volume":"17","author":"Olesen","year":"2018","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1007\/s13311-020-00967-7_bib2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","article-title":"Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study","volume":"52","author":"Buse","year":"2012","journal-title":"Headache."},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10194-019-0985-0","article-title":"Primary headaches during lifespan","volume":"20","author":"Straube","year":"2019","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jval.2012.08.2212","article-title":"Cost and predictors of lost productive time in chronic migraine and episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study","volume":"16","author":"Serrano","year":"2013","journal-title":"Value Health"},{"issue":"10","key":"10.1007\/s13311-020-00967-7_bib5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/JOM.0b013e31822cff3c","article-title":"A case study for calculating employer costs for lost productive time in episodic migraine and chronic migraine: results of the American Migraine Prevalence and Prevention Study","volume":"53","author":"Stewart","year":"2011","journal-title":"J Occup Environ Med"},{"issue":"21","key":"10.1007\/s13311-020-00967-7_bib6","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1212\/WNL.0000000000003963","article-title":"Hypothalamus as a mediator of chronic migraine: Evidence from high-resolution fMRI","volume":"88","author":"Schulte","year":"2017","journal-title":"Neurology."},{"issue":"Pt 7","key":"10.1007\/s13311-020-00967-7_bib7","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/brain\/aww097","article-title":"The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks","volume":"139","author":"Schulte","year":"2016","journal-title":"Brain."},{"issue":"Pt 1","key":"10.1007\/s13311-020-00967-7_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/brain\/awt320","article-title":"Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks","volume":"137","author":"Maniyar","year":"2014","journal-title":"Brain."},{"issue":"10","key":"10.1007\/s13311-020-00967-7_bib9","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1526-4610.2007.00776.x","article-title":"Hypothalamic activation in spontaneous migraine attacks","volume":"47","author":"Denuelle","year":"2007","journal-title":"Headache."},{"issue":"8","key":"10.1007\/s13311-020-00967-7_bib10","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1136\/jnnp.2004.050633","article-title":"Occipital activation in glyceryl trinitrate induced migraine with visual aura","volume":"76","author":"Afridi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1007\/s13311-020-00967-7_bib11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1526-4610.1999.3907469.x","article-title":"The occipital cortex is hyperexcitable in migraine: experimental evidence","volume":"39","author":"Aurora","year":"1999","journal-title":"Headache."},{"issue":"10","key":"10.1007\/s13311-020-00967-7_bib12","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/j.1526-4610.2011.02013.x","article-title":"Photoreactivity of the occipital cortex measured by functional magnetic resonance imaging-blood oxygenation level dependent in migraine patients and healthy volunteers: pathophysiological implications","volume":"51","author":"Martin","year":"2011","journal-title":"Headache."},{"issue":"Suppl 22","key":"10.1007\/s13311-020-00967-7_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/0333102498018S2204","article-title":"The occipital cortex as a generator of migraine aura","volume":"18","author":"Welch","year":"1998","journal-title":"Cephalalgia."},{"issue":"8","key":"10.1007\/s13311-020-00967-7_bib14","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1001\/archneur.62.8.1270","article-title":"A positron emission tomographic study in spontaneous migraine","volume":"62","author":"Afridi","year":"2005","journal-title":"Arch Neurol"},{"issue":"Pt 4","key":"10.1007\/s13311-020-00967-7_bib15","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/brain\/awh416","article-title":"A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate","volume":"128","author":"Afridi","year":"2005","journal-title":"Brain."},{"issue":"5","key":"10.1007\/s13311-020-00967-7_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/NRL.0b013e31822d109c","article-title":"Risk of development of medication overuse headache with nonsteroidal anti-inflammatory drug therapy for migraine: a critically appraised topic","volume":"17","author":"Starling","year":"2011","journal-title":"Neurologist"},{"issue":"7","key":"10.1007\/s13311-020-00967-7_bib17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia."},{"issue":"7","key":"10.1007\/s13311-020-00967-7_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia."},{"issue":"6","key":"10.1007\/s13311-020-00967-7_bib19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache."},{"key":"10.1007\/s13311-020-00967-7_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1129-2377-15-54","article-title":"Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.","volume":"15","author":"Khalil","year":"2014","journal-title":"J Headache Pain"},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-016-0591-3","article-title":"A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience","volume":"17","author":"Negro","year":"2015","journal-title":"J Headache Pain"},{"key":"10.1007\/s13311-020-00967-7_bib22","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1186\/s40064-015-1636-9","article-title":"OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study","volume":"4","author":"Negro","year":"2015","journal-title":"Springerplus."},{"issue":"8","key":"10.1007\/s13311-020-00967-7_bib23","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/ene.13657","article-title":"Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal","volume":"25","author":"Andreou","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-020-00967-7_bib24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0072-9752(07)01511-4","article-title":"Botulism","volume":"91","author":"Johnson","year":"2008","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"10.1007\/s13311-020-00967-7_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/toxins2040665","article-title":"Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering","volume":"2","author":"Binz","year":"2010","journal-title":"Toxins (Basel)"},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4610.2004.04007.x","article-title":"Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy","volume":"44","author":"Durham","year":"2004","journal-title":"Headache."},{"issue":"3","key":"10.1007\/s13311-020-00967-7_bib27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.pain.2010.07.029","article-title":"Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis","volume":"151","author":"Gazerani","year":"2010","journal-title":"Pain."},{"issue":"15","key":"10.1007\/s13311-020-00967-7_bib28","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1523\/JNEUROSCI.5490-08.2009","article-title":"Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential","volume":"29","author":"Meng","year":"2009","journal-title":"J Neurosci"},{"issue":"11","key":"10.1007\/s13311-020-00967-7_bib29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/0333102414527648","article-title":"Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains","volume":"34","author":"Burstein","year":"2014","journal-title":"Cephalalgia."},{"issue":"9","key":"10.1007\/s13311-020-00967-7_bib30","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0333102416636843","article-title":"Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?","volume":"36","author":"Zhang","year":"2016","journal-title":"Cephalalgia."},{"issue":"2","key":"10.1007\/s13311-020-00967-7_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain."},{"issue":"42","key":"10.1007\/s13311-020-00967-7_bib32","doi-asserted-by":"crossref","first-page":"18197","DOI":"10.1073\/pnas.1007125107","article-title":"SNARE tagging allows stepwise assembly of a multimodular medicinal toxin","volume":"107","author":"Darios","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1007\/s13311-020-00967-7_bib33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.neuroscience.2013.09.002","article-title":"Cortical spreading depression induces oxidative stress in the trigeminal nociceptive system","volume":"253","author":"Shatillo","year":"2013","journal-title":"Neuroscience."},{"key":"10.1007\/s13311-020-00967-7_bib34","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fncel.2015.00287","article-title":"Hunting for origins of migraine pain: cluster analysis of spontaneous and capsaicin-induced firing in meningeal trigeminal nerve fibers","volume":"9","author":"Zakharov","year":"2015","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"10.1007\/s13311-020-00967-7_bib35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/01.j.pain.0000460325.25762.c0","article-title":"Modulation of nociceptive dural input to the trigeminocervical complex through GluK1 kainate receptors","volume":"156","author":"Andreou","year":"2015","journal-title":"Pain."},{"issue":"4","key":"10.1007\/s13311-020-00967-7_bib36","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00588643","article-title":"The differentiation of axonal and soma-dendritic spike activity","volume":"321","author":"Fussey","year":"1970","journal-title":"Pflugers Arch"},{"issue":"2","key":"10.1007\/s13311-020-00967-7_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neubiorev.2003.12.003","article-title":"The orofacial formalin test","volume":"28","author":"Raboisson","year":"2004","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"10.1007\/s13311-020-00967-7_bib38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/j.pain.0000000000000478","article-title":"Nonparalytic botulinum molecules for the control of pain","volume":"157","author":"Mangione","year":"2016","journal-title":"Pain."},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s10194-019-1066-0","article-title":"Mechanisms of migraine as a chronic evolutive condition","volume":"20","author":"Andreou","year":"2019","journal-title":"J Headache Pain"},{"issue":"3","key":"10.1007\/s13311-020-00967-7_bib40","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/ern.10.16","article-title":"Animal models of headache: from bedside to bench and back to bedside","volume":"10","author":"Andreou","year":"2010","journal-title":"Expert Rev Neurother"},{"key":"10.1007\/s13311-020-00967-7_bib41","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2019.02.002","article-title":"Nitroglycerin as a comparative experimental model of migraine pain: From animal to human and back","volume":"177","author":"Demartini","year":"2019","journal-title":"Prog Neurobiol"},{"issue":"12","key":"10.1007\/s13311-020-00967-7_bib42","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1177\/0333102414566862","article-title":"Effects of peripheral FAAH blockade on NTG-induced hyperalgesia--evaluation of URB937 in an animal model of migraine","volume":"35","author":"Greco","year":"2015","journal-title":"Cephalalgia."},{"issue":"4","key":"10.1007\/s13311-020-00967-7_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14728214.2018.1552939","article-title":"Emerging drugs for migraine treatment: an update","volume":"23","author":"Lambru","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"issue":"5","key":"10.1007\/s13311-020-00967-7_bib44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton","year":"2007","journal-title":"Neurology."},{"issue":"5","key":"10.1007\/s13311-020-00967-7_bib45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1046\/j.1526-4610.1997.3705277.x","article-title":"Prevalence and clinical features of chronic daily headache in a headache clinic","volume":"37","author":"Srikiatkhachorn","year":"1997","journal-title":"Headache."},{"key":"10.1007\/s13311-020-00967-7_bib46","series-title":"Headache and Other Head Pain","author":"Wolff","year":"1948"},{"issue":"2","key":"10.1007\/s13311-020-00967-7_bib47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.neuroscience.2009.03.019","article-title":"Neurobiology of migraine","volume":"161","author":"Goadsby","year":"2009","journal-title":"Neuroscience."},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10194-009-0170-y","article-title":"Does sumatriptan cross the blood-brain barrier in animals and man?","volume":"11","author":"Tfelt-Hansen","year":"2010","journal-title":"J Headache Pain"},{"issue":"Pt 7","key":"10.1007\/s13311-020-00967-7_bib49","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/brain\/aww096","article-title":"Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine","volume":"139","author":"Schankin","year":"2016","journal-title":"Brain."},{"key":"10.1007\/s13311-020-00967-7_bib50","doi-asserted-by":"crossref","unstructured":"Johnson KW, Morin SM, Wroblewski VJ, Johnson MP. Peripheral and central nervous system distribution of the CGRP neutralizing antibody [(125)I] galcanezumab in male rats. Cephalalgia. 2019:333102419844711.","DOI":"10.1177\/0333102419844711"},{"issue":"Pt 5","key":"10.1007\/s13311-020-00967-7_bib51","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/brain\/119.5.1419","article-title":"Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism","volume":"119","author":"Hoskin","year":"1996","journal-title":"Brain."},{"issue":"30","key":"10.1007\/s13311-020-00967-7_bib52","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1523\/JNEUROSCI.0576-17.2017","article-title":"Selective Inhibition of Trigeminovascular Neurons by Fremanezumab: A Humanized Monoclonal Anti-CGRP Antibody","volume":"37","author":"Melo-Carrillo","year":"2017","journal-title":"J Neurosci"},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1468-1331.1994.tb00053.x","article-title":"A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks","volume":"1","author":"Thomsen","year":"1994","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1007\/s13311-020-00967-7_bib54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0014-2999(02)02188-X","article-title":"Effects of nimesulide on nitric oxide-induced hyperalgesia in humans--a neurophysiological study","volume":"450","author":"Sandrini","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 4","key":"10.1007\/s13311-020-00967-7_bib55","first-page":"S182","article-title":"Central sensitization theory of migraine: clinical implications","volume":"46","author":"Dodick","year":"2006","journal-title":"Headache."},{"issue":"2-3","key":"10.1007\/s13311-020-00967-7_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3959(00)00478-4","article-title":"Deconstructing migraine headache into peripheral and central sensitization","volume":"89","author":"Burstein","year":"2001","journal-title":"Pain."},{"issue":"6609","key":"10.1007\/s13311-020-00967-7_bib57","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/384560a0","article-title":"Sensitization of meningeal sensory neurons and the origin of headaches","volume":"384","author":"Strassman","year":"1996","journal-title":"Nature."},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-018-0851-5","article-title":"Altered muscle activity during rest and during mental or physical activity is not a trait symptom of migraine - a neck muscle EMG study","volume":"19","author":"Luedtke","year":"2018","journal-title":"J Headache Pain"},{"issue":"3","key":"10.1007\/s13311-020-00967-7_bib59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2302\/kjm.60.82","article-title":"Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine","volume":"60","author":"Messlinger","year":"2011","journal-title":"Keio J Med"},{"issue":"9","key":"10.1007\/s13311-020-00967-7_bib60","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/j.1526-4610.2012.02212.x","article-title":"CGRP and NO in the trigeminal system: mechanisms and role in headache generation","volume":"52","author":"Messlinger","year":"2012","journal-title":"Headache."},{"issue":"14","key":"10.1007\/s13311-020-00967-7_bib61","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.0b013e3182a6cb72","article-title":"Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine","volume":"81","author":"Cernuda-Morollon","year":"2013","journal-title":"Neurology."},{"issue":"6","key":"10.1007\/s13311-020-00967-7_bib62","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/head.12372","article-title":"CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine","volume":"54","author":"Cernuda-Morollon","year":"2014","journal-title":"Headache."},{"issue":"5","key":"10.1007\/s13311-020-00967-7_bib63","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","article-title":"OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine","volume":"156","author":"Cernuda-Morollon","year":"2015","journal-title":"Pain."},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"Goadsby","year":"1993","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1007\/s13311-020-00967-7_bib65","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-020-00967-7_bib66","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","article-title":"Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial","volume":"372","author":"Ho","year":"2009","journal-title":"Lancet."},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s10194-020-01134-1","article-title":"The fifth cranial nerve in headaches","volume":"21","author":"Edvinsson","year":"2020","journal-title":"J Headache Pain"},{"issue":"6","key":"10.1007\/s13311-020-00967-7_bib68","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1517\/13543780902913792","article-title":"Therapeutic potential of novel glutamate receptor antagonists in migraine","volume":"18","author":"Andreou","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"10.1007\/s13311-020-00967-7_bib69","doi-asserted-by":"crossref","first-page":"e01215","DOI":"10.1002\/brb3.1215","article-title":"CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta-analysis","volume":"9","author":"Han","year":"2019","journal-title":"Brain Behav"},{"issue":"4","key":"10.1007\/s13311-020-00967-7_bib70","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol Rev"},{"issue":"9","key":"10.1007\/s13311-020-00967-7_bib71","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.tips.2016.06.002","article-title":"Wiping Out CGRP: Potential Cardiovascular Risks","volume":"37","author":"MaassenVanDenBrink","year":"2016","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1007\/s13311-020-00967-7_bib72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tips.2018.11.003","article-title":"CGRP\/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization?","volume":"40","author":"Majima","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"10.1007\/s13311-020-00967-7_bib73","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/head.13439","article-title":"Basic Considerations for the Use of Monoclonal Antibodies in Migraine","volume":"58","author":"Levin","year":"2018","journal-title":"Headache."},{"key":"10.1007\/s13311-020-00967-7_bib74","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nbd.2015.04.011","article-title":"Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents","volume":"79","author":"Ramachandran","year":"2015","journal-title":"Neurobiol Dis"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00967-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00967-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00967-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:01:40Z","timestamp":1761807700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923012163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1878747923012163"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00967-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double-Binding Botulinum Molecule with Reduced Muscle Paralysis: Evaluation in In Vitro and In Vivo Models of Migraine","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00967-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}